DxTerity is leading the "from home" genomics revolution with the introduction of low cost, comprehensive, Direct-to-Patient genomic study services.  We combine state of the art digital recruitment with eConsent, ePROs and a full complement of clinical genomic laboratory services.


Using DxTerity's genomics platform, fingerstick blood can be safely collected & shipped to DxTerity via US mail for non-clinical analysis. Our DxCollect system enables Research or Investigational Use Only testing that may lead to the clearance, approval, or licensure of a new IVD for clinical diagnostic use.


DxTerity at AMP November 5-7th Booth 405

DxTerity launches Direct to Patient Genomic Clinical Studies Service

DxTerity Shows Positive Results in Radiation Toxicity Prediction Assay Eyes Larger study

DxTerity Announces $7.5 Million in Financing from SWK Funding

Duke Awarded $10.4 Million Contract To Continue Developing Radiation Test

DxTerity Diagnostics featured in Clinical Omics

LA Business Journal - Focus on Healthcare

DxTerity Receives CAP Accreditation

DxTerity Announces CLIA Licensure

REDI-DX Radiation Test Performs Well in NATO Study

REDI-Dx Wins 2013 Product of the Year Award

DxTerity Wins SBIR to Develop Radiation Toxicity Test

DxTerity REDI-Dx Functional Exercise with Scottsdale Health and GER911